Form 4: Elanco Animal Health CEO Jeffrey Simmons Acquires Deferred Stock Units

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC Form 4 filing.

Summary

• On September 6, 2024, Jeffrey N. Simmons, the President, CEO, and Director of Elanco Animal Health Inc., acquired 183.5149 deferred stock units.
• These deferred stock units represent the right to receive one share of Elanco's common stock or the cash equivalent.
• The transaction was reported on September 10, 2024.
• Following the reported transaction, Simmons directly owns 3,307.3225 derivative securities.
• The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing an executive's acquisition of deferred stock units. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Industry Context

This filing is a routine disclosure of executive compensation in the form of deferred stock units, which is a common practice in publicly traded companies to align executive interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages often include deferred stock units to incentivize long-term performance.
• Companies like Zoetis and Merck Animal Health also utilize similar compensation strategies for their executives.
• The specific terms of Elanco's Executive Deferral and Stock Match Plan would need to be compared to those of its peers to assess its relative generosity and effectiveness.

Stakeholder Impact

• The acquisition of deferred stock units by the CEO aligns his interests with those of the shareholders, potentially incentivizing him to improve the company's performance and increase shareholder value.

Key Dates